NeuroXess Completes 700 Million Yuan Series B Financing to Advance Brain-Computer Interface Mass Production and BCI+AI R&D
NeuroXess announced on October 28 that it has completed a 700 million yuan Series B financing, jointly led by SDIC Jili, Shenzhen Capital Group, and Qinzhi Capital, with participation from SMIC Juyuan, Huangpu Investment, Cornerstone Capital, IDG Capital, and others. The funds will be used for multicenter clinical trials and registration approval of the "Three All" brain-computer interface system, mass production construction of the super factory, next-generation product R&D, and exploration of BCI+AI integration. The company said it has completed 65 clinical trials; its "Three All" system launched a GCP registration clinical trial on July 7, 2026, at Huashan Hospital affiliated with Fudan University, and it plans a 14,300-square-meter super factory to achieve capacity of tens of thousands of units.
Why read this
AI score 60
Financing details and clinical, mass production, and BCI+AI R&D plans were disclosed together, offering insight into the industrialization progress of domestic implantable brain-computer interfaces.
Topics
Body · AI translation
NeuroHawk Technology announced on October 28 that it has completed a 700 million yuan Series B financing round. The round was co-led by SDIC Jili, Shenzhen Capital Group, and Qinzhi Capital, with participation from SMIC Juyuan, Huangpu Investment, Cornerstone Capital, IDG Capital, and other institutions, while existing shareholders including Shanda and Zhongping Capital continued their support.
NeuroHawk Technology stated that the proceeds from this round will be used for multicenter clinical trials and registration approval of the "fully implantable, fully wireless, fully functional" ("three fully") brain-computer interface system, mass-production construction of the super factory, research and development of next-generation products, and exploration of BCI+AI integration. The investor structure covers central state-owned enterprise funds, local state-owned capital, semiconductor industry capital, healthcare funds, hard-tech investment institutions, and comprehensive venture capital firms. On the clinical and industrialization front, NeuroHawk Technology disclosed that the company has completed 65 clinical trials.
On July 7, 2026, the "three fully" brain-computer interface system launched a GCP registration clinical trial at Huashan Hospital Affiliated to Fudan University, with Mao Ying's team serving as the principal investigator, jointly carried out with nearly 20 tertiary hospitals across the country. The company stated that this is the first domestic subdural semi-invasive brain-computer interface product to enter the national Class III medical device registration clinical stage.
On the mass-production front, NeuroHawk Technology has started construction of a "super factory" with a planned area of 14,300 square meters, targeting ten-thousand-unit-level production capacity.
On the research and development front, the company's next-generation products will focus on iteration and performance optimization of language brain-computer interfaces and accelerate the development of visual brain-computer interfaces; the BCI+AI direction will revolve around invoking AI through intent, connecting tools, and driving environments, exploring a BCI+AI real physical world model. The company aims to drive large-scale implementation of its products in the medical market within two years.
Public information shows that NeuroHawk Technology was founded in 2021 by Tao Hu and focuses on the research, development, and industrialization of implantable flexible brain-computer interface technology.